Oncolytics Biotech (NASDAQ: ONCY) appoints new strategy and biostatistics leaders

Rhea-AI Filing Summary

Oncolytics Biotech, Inc. filed a current report to disclose leadership changes. The company announced that John McAdory has been appointed as Executive Vice President of Strategy and Operations and Yujun Wu has been appointed as Vice President, Head of Biostatistics, signaling additions to its senior management team.

The company also states that this report on Form 8-K, including the attached press release, is incorporated by reference as an exhibit to its Registration Statement on Form F-3 (File No. 333-289819). No financial results or major transactions are described in this report.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001129928 0001129928 2026-01-14 2026-01-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

Oncolytics Biotech, Inc.

(Exact name of registrant as specified in its charter)

Alberta, Canada	001-38512	26-3847449
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4350 Executive Drive, Suite 325 San Diego, CA 92121	92121
(Address of principal executive offices)	(Zip Code)
(403) 670-7377
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares, no par value per share		ONCY		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On January 14, 2026, Oncolytics Biotech, Inc. (the “Company”) issued a press release announcing the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

In addition to any of the Company’s filings with the U.S. Securities and Exchange Commission that automatically incorporate all filings made by the Company pursuant to Sections 13(a), 13(c), 14, and 15(d) of the U.S. Securities and Exchange Act of 1934, as amended, this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is hereby incorporated by reference as an exhibit to the Company’s Registration Statement on Form F-3 (File No. 333-289819).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release issued by Oncolytics Biotech, Inc., dated as of January 14, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 14, 2026

	ONCOLYTICS BIOTECH, INC.
	By:	/s/ Kirk Look
	Name:	Kirk Look
	Title:	Chief Financial Officer

FAQ

What leadership changes did Oncolytics Biotech (ONCY) report?

Oncolytics Biotech, Inc. reported the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics.

What is the main purpose of this Oncolytics Biotech (ONCY) Form 8-K?

The Form 8-K reports executive appointments at Oncolytics Biotech, Inc. and provides a press release as an exhibit describing these leadership changes.

Who is the new Executive Vice President of Strategy and Operations at Oncolytics Biotech (ONCY)?

John McAdory has been appointed Executive Vice President of Strategy and Operations at Oncolytics Biotech, Inc., as disclosed in the report.

Who is the new Vice President, Head of Biostatistics at Oncolytics Biotech (ONCY)?

Yujun Wu has been appointed Vice President, Head of Biostatistics at Oncolytics Biotech, Inc., according to the report.

How is this Form 8-K related to Oncolytics Biotech’s Form F-3 registration?

The report states that this Form 8-K, including Exhibit 99.1 (the press release), is incorporated by reference as an exhibit to Oncolytics Biotech, Inc.’s Registration Statement on Form F-3 (File No. 333-289819).

Does this Oncolytics Biotech (ONCY) 8-K include financial results or major transactions?

The report focuses on management appointments and the incorporation by reference into a Form F-3 registration statement; it does not describe financial results or major transactions.